THE SCIENCE
Protecting T cells during their most critical function
Fas Ligand (FasL) is a death signal many tumors use to delete activated T cells on contact. Gamma’s lead antibody, M3T01, is designed to neutralize FasL so T cells can persist, infiltrate tumors, and destroy cancer cells. Follow along to discover the science behind this promising new therapy.
What Drives Our Approach
The Problem
Tumors shut down the immune system
For all the progress of modern immunotherapy, many cancers still evade treatment. One key reason: tumors have evolved a way to delete T cells before they can act.
Fas Ligand (FasL) is a molecule found within the tumor microenvironment in many cancers. When T cells come in contact with FasL, a self-destruct sequence is initiated. This crippling of the immune system allows tumors to grow and spread unimpeded. Until we protect the immune cells from being destroyed, even the most potent activating immunotherapies will have limited reach.
Our Solution
Shielding and protecting the body’s natural defense system
Gamma Biotherapeutics’ lead program, M3T01, is the first FasL-neutralizing monoclonal antibody to enter clinical trials.
M3T01 is a fully human monoclonal antibody designed for clinical performance: high potency, long half-life, and a safety profile that supports use in combination with other immunotherapies. By blocking FasL, M3T01 allows T cells to persist and infiltrate tumors, which may augment the efficacy of immune checkpoint inhibitors and adoptive cell therapies. Through combination strategies, we aim to not just release the brakes, but shield the engine itself.
IN The LAB
Research in motion
In partnership with Providence Cancer Institute, Gamma Biotherapeutics is advancing M3T01 through its first-in-human Phase 1 trial. Inside the lab, our team conducts ongoing testing and analysis to translate molecular insight into real-world therapeutic potential.
